KaloBios Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company's contract revenue was $16,000 against $3,018,000 a year ago. Loss from operations was $8,323,000 against $1,147,000 a year ago. Net loss was $8,574,000 or $0.55 per basic and diluted share against $1,131,000 or $0.56 per basic and diluted share a year ago.

KaloBios Pharmaceuticals, Inc. Presents at Credit Suisse 2013 Antibody Day, May-10-2013 10:30 AM. Venue: New York, New York, United States. Speakers: David W. Pritchard, Chief Executive Officer, President and Director.

Sanofi Pasteur Limited and KaloBios Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi Pasteur for the investigation of KB001A, an antibody fragment, intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa (Pa) in mechanically-ventilated patients. The Fast Track Drug Development Program of the FDA is designed to facilitate the clinical development and expedite the review of new drugs and vaccines that are intended to treat or prevent serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The joint announcement was made on this second day of the BIO International Convention, the 20th annual meeting of the world's large biotechnology organization. Most serious Pa infections occur in hospitalized and critically or chronically ill patients--primarily affecting the respiratory system in susceptible individuals--and are a serious clinical problem due to the bacteria's resistance to antibiotics. Sanofi Pasteur, which is responsible for the clinical development under the terms of the agreement with KaloBios, is currently conducting a phase I trial of the monoclonal antibody in the United States and has started the planning of a phase IIb study. Under the terms of the current agreement, Sanofi Pasteur has worldwide rights to KaloBios' KB001A technology for all disease indications related to Pa infections, except cystic fibrosis and bronchiectasis, the rights in which were retained by KaloBios, and Sanofi Pasteur has the option to obtain at a later date.